Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients
暂无分享,去创建一个
H. Goossens | P. V. van Dam | Z. Berneman | E. Fransen | E. Roelant | M. Peeters | S. Kumar-Singh | W. Vanden Berghe | S. Malhotra-Kumar | A. Hotterbeekx | C. Vulsteke | Annelies Janssens | M. Huizing | P. Moons | L. Croes | F. D. De Winter | A. Konnova | R. Jairam | V. Van averbeke | D. Le Blon | W. Lybaert | B. Jongers | P. V. van Dam | F. D. de Winter | Annelies Janssens
[1] P. Edison,et al. Long covid—mechanisms, risk factors, and management , 2021, BMJ.
[2] G. Saini,et al. Cancer as a prospective sequela of long COVID‐19 , 2021, BioEssays : news and reviews in molecular, cellular and developmental biology.
[3] Y. Crow,et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19 , 2021, Science Immunology.
[4] P. V. van Dam,et al. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests , 2021, European Journal of Cancer.
[5] A. Coolen,et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients , 2021, Cancer Cell.
[6] Xiawei Wei,et al. Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy , 2021, Cells.
[7] L. Notarangelo,et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients , 2020, JCI insight.
[8] James Batchelor,et al. Inflammatory phenotyping predicts clinical outcome in COVID-19 , 2020, Respiratory Research.
[9] A. Abbas. The Surprising Story of IL-2: From Experimental Models to Clinical Application. , 2020, The American journal of pathology.
[10] T. Yeo,et al. Viral dynamics and immune correlates of COVID-19 disease severity , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Keith Sigel,et al. An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.
[12] Z. Hu,et al. The predictive value of serum amyloid A and C-reactive protein levels for the severity of coronavirus disease 2019. , 2020, American journal of translational research.
[13] Eric Song,et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.
[14] P. V. van Dam,et al. SARS-CoV-2 and cancer: Are they really partners in crime? , 2020, Cancer Treatment Reviews.
[15] Rodolfo Daniel Cervantes-Villagrana,et al. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies , 2020, Signal Transduction and Targeted Therapy.
[16] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.
[17] N. Hens,et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a prospective cross-sectional study of residual samples , 2020, medRxiv.
[18] D. Kerr,et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.
[19] W. Niu,et al. Cancer associates with risk and severe events of COVID‐19: A systematic review and meta‐analysis , 2020, International journal of cancer.
[20] Axel Haverich,et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.
[21] G. Gao,et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[22] M. Santillana,et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.
[23] H. Lenz,et al. 12‐Chemokine signature, a predictor of tumor recurrence in colorectal cancer , 2020, International journal of cancer.
[24] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[25] K. D. de Visser,et al. Immune crosstalk in cancer progression and metastatic spread: a complex conversation , 2020, Nature Reviews Immunology.
[26] Tiantian Han,et al. Coronavirus infections and immune responses , 2020, Journal of medical virology.
[27] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[28] Jungsook Cho,et al. Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers , 2020, Cancers.
[29] C. Marosi,et al. GDF‐15 in solid vs non‐solid treatment‐naïve malignancies , 2019, European journal of clinical investigation.
[30] S. Ziegler,et al. TSLP: from allergy to cancer , 2019, Nature Immunology.
[31] George H Sack,et al. Serum amyloid A – a review , 2018, Molecular Medicine.
[32] B. Fridley,et al. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML , 2018, Leukemia.
[33] Angela G. Fleischman,et al. The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies , 2018, Cancers.
[34] Jennifer R. Grandis,et al. Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.
[35] Hideo Baba,et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.
[36] T. McGaha,et al. Type I Interferon in Chronic Virus Infection and Cancer. , 2017, Trends in immunology.
[37] G. Ciliberto,et al. Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays , 2016, Mediators of inflammation.
[38] T. Gajewski,et al. The host STING pathway at the interface of cancer and immunity. , 2016, The Journal of clinical investigation.
[39] K. Uzawa,et al. Tie2 Regulates Tumor Metastasis of Oral Squamous Cell Carcinomas , 2016, Journal of Cancer.
[40] W. Jia,et al. A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients , 2014, International journal of cancer.
[41] J. Passweg,et al. Role of tumour angiogenesis in haematological malignancies. , 2014, Swiss medical weekly.
[42] R. Pfeiffer,et al. Circulating inflammation markers and prospective risk for lung cancer. , 2013, Journal of the National Cancer Institute.
[43] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[44] L. Coussens,et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.
[45] T. Iwama,et al. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. , 2009, International journal of oncology.
[46] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[47] B. Hempstead,et al. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. , 2007, Trends in cardiovascular medicine.
[48] F. Balkwill. TNF-α in promotion and progression of cancer , 2006, Cancer and Metastasis Reviews.
[49] F. Balkwill. TNF-alpha in promotion and progression of cancer. , 2006, Cancer metastasis reviews.
[50] Peter Carmeliet,et al. VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.
[51] Guan-Cheng Li,et al. Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis. , 2002, World journal of gastroenterology.
[52] M. Skinner,et al. Acute‐Phase Proteins or Tumour Markers: The Role of SAA, SAP, CRP and CEA as Indicators of Metastasis in a Broad Spectrum of Neoplastic Diseases , 1984, Scandinavian journal of immunology.